|
Drug Information
Pharmacokinetics
| Indication
& Dosage | Action
| Interactions
Adverse
Effect & Precautions |
Brands available in Market
Indication
& Dosage
IM/IV
ACUTE LYMPHOCYTIC LEUKAEMIA FOR INDUCTION OF REMISSION. NOT FOR
MAINTENANCE THERAPY: As a part of multidrug iduction regimens: IV: 1000 IU/kg/day
for 10 successive days as part of regimen with Prednisone, Vincristine
sulphate or IM: 6000 IU/m2 on Days 4,7,10,13,16,19,22,25,28 of the
treatment period with prednisone and vincristine sulpahte.
IV
SOLE AGENT FOR INDUCTION OF REMISSION: Adults and children: 200 IU/KG
intravenously daily for 28 days. NOTE: When administered IV, drug should
be given over 30 mins along with normal saline/5% dextrose.
Rapidly depletes asparagine from malignant cells which depend on exogenous sources for survival. Normal cells can synthesize asparagine and are affected less. L-Asparaginase induces remission in some patients with acute lymphocytic leukaemie.
Interactions
Vincristine and Prednisone: Associated with increased toxicity.
Methotrexate: Effect on malignant cells diminished or abolished as
long as plasma asparginase levels are suppressed.
Cytarabine: Synegistic effect.
Lab Tests: Thyroid function tests: Interferes with its
interpretation.
Adverse
Effect & Precautions
Nausea, vomiting, headache, fever, abdominal pain, hyperglycaemia
leading to coma, hypersensitivity, renal damge, coagulation
defects, trombosis, CNS depression or hyperexcitability, acute
haemorrhageic pancreatits.
Precaution: Hypersenstivity
Pregnancy: Use only if potential benefit justifies risk to the
foetus
Breast Feeding: Discontinue nursing or the drug.
Man: Use with caution.
LEUCOGINASE
VHB
INJ
10000IU
VIAL
796.00
LEUNASE
Biochem
INJ
10000KU
VIAL
1095.00
